News – Page 1076 – Endpoints News

Andy Boyer joins Teva exodus; Achaogen shuffles executive lineup

8 years ago

Celgene forges cancer pact with CRT; FDA OKs Pfizer's Xeljanz as treatment for psoriatic arthritis

8 years ago

Four months after patient death, FDA's hold lifted on Alnylam's fitusiran

8 years ago

The 50 most active biotech VC funds in 2017

8 years ago

Amicus CEO lobbied FDA to reverse FDA’s rejection of migalastat, claiming a delay of up to 7 years

8 years ago

Grail taps Genentech vet Jennifer Cook as CEO, building expectations for 2018

8 years ago

Novartis oncology CEO Bruno Strigini is calling it quits

8 years ago

One of Merck's pivotal stomach cancer trials for Keytruda flops, just months after an FDA OK

8 years ago

Galapagos snags co-promotion rights on filgotinib — just before Gilead’s lock-up pact expires

8 years ago

Jnana launches with $50M to spotlight an unexplored protein territory

8 years ago

Pfizer's Ixifi gets approved as third Remicade biosimilar; Novo Nordisk licenses reMYND's diabetes program in ...

8 years ago

Bristol-Myers teams up with Opdivo maker Ono Pharmaceutical on new I/O programs

8 years ago

The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate

8 years ago

Teva axing 14,000 workers, putting R&D and manufacturing facilities on the block in massive restructuring

8 years ago

Relay grabs $63M to pay for a drug discovery trip into the fourth dimension

8 years ago

Andreessen drums up a $450M fund to back their vision for engineering biology

8 years ago

Its underlying biology 'too complicated' for further investment, Atlas-seeded Raze signs off

8 years ago

Atlas and OrbiMed back Boston's Kyn in $49M round to pursue immunometabolism therapies

8 years ago

Eli Lilly highlights key R&D catalysts for 2018; Vernalis and Daiichi Sankyo work together on cancer targets

8 years ago

NEA leads a big syndicate on $100M mega-round for Allakos

8 years ago

Daiichi ditches Nektar following cancer drug flop

8 years ago

Sanofi faces a make-or-break year, saying it’s ready to put a 3-prong R&D strategy to a pivotal test

8 years ago

Teva sharpens ax, preps brutal cuts in R&D and across the group in face of crushing debt

8 years ago

Yervoy inventor's oncology startup Pionyr gets $62M for tumor-fighting tech

8 years ago

First page Previous page 1073 1074 107510761077 1078 1079 Next page Last page